Phase I trial of the combination of the multikinase inhibitor nintedanib plus letrozole: A window of opportunity trial in adjuvant hormone-receptor positive breast cancer (HRPBC).

被引：0
|
作者：
Rodriguez, Laura Medina
Guerra, Juan Antonio
Malon, Diego
Laura, Rodriguez
Colomer, Ramon
Quintela-Fandino, Miguel
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS615
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS615
引用
收藏
页数：2
相关论文
共 50 条
  • [11] A phase I trial to evaluate the safety of the addition of alisertib to fulvestrant in hormone receptor positive (HR plus ), advanced breast cancer
    Haddad, T. C.
    D'Assoro, A. B.
    Suman, V. J.
    Opyrchal, M.
    Goetz, M. P.
    Ingle, J. N.
    CANCER RESEARCH, 2016, 76
  • [12] Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance).
    Dickler, Maura N.
    Barry, William Thomas
    Cirrincione, Constance T.
    Ellis, Matthew James
    Moynahan, Mary Ellen
    Innocenti, Federico
    Hurria, Arti
    Rugo, Hope S.
    Lake, Diana
    Hahn, Olwen Mary
    Schneider, Bryan P.
    Tripathy, Debu
    Winer, Eric P.
    Hudis, Clifford A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [13] Phase I trial of daily PI3Kα inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
    Shah, Payal Deepak
    Modi, Shanu
    Datko, Farrah Mikhail
    Moynahan, Mary Ellen
    Zamora, Stephen
    D'Andrea, Gabriella
    Lake, Diana
    Goldfarb, Sharl Beth
    Patil, Sujata
    Singh, Sharat
    Langley, Emma J.
    Kim, Phillip Sangwook
    Covey, Anne M.
    Caravella, Betty Ann
    Berger, Michael F.
    Lacouture, Mario E.
    Hudis, Clifford A.
    Baselga, Jose
    Chandarlapaty, Sarat
    Dickler, Maura N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [14] Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer
    Francisco J. Esteva
    Stacy L. Moulder
    Ana M. Gonzalez-Angulo
    Joe Ensor
    James L. Murray
    Marjorie C. Green
    Kimberly B. Koenig
    Mong-Hong Lee
    Gabriel N. Hortobagyi
    Sai-Ching Yeung
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 63 - 72
  • [15] A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer
    Robert W. Carlson
    Anne O’Neill
    Tatiana Vidaurre
    Henry L. Gomez
    Sunil S. Badve
    George W. Sledge
    Breast Cancer Research and Treatment, 2012, 133 : 1049 - 1056
  • [16] A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer
    Carlson, Robert W.
    O'Neill, Anne
    Vidaurre, Tatiana
    Gomez, Henry L.
    Badve, Sunil S.
    Sledge, George W.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) : 1049 - 1056
  • [17] Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205
    Li, T.
    Christos, P. J.
    Sparano, J. A.
    Hershman, D. L.
    Hoschander, S.
    O'Brien, K.
    Wright, J. J.
    Vahdat, L. T.
    ANNALS OF ONCOLOGY, 2009, 20 (04) : 642 - 647
  • [18] A Randomized Window of Opportunity Study of Preoperative Letrozole and Simvastatin Versus Letrozole Alone in Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
    Sacks, Ruth
    Haas, Elizabeth
    Jones, Jade
    Bhave, Manali
    Gogineni, Keerthi
    Meisel, Jane
    Smith-Graziani, Demetria
    Pakkala, Suchi
    Friend, Sarah
    Arciero, Cletus
    Postlewait, Lauren
    Farley, Clara
    Graham, Cathy
    Styblo, Toncred
    Rizzo, Monica
    Pickett, Rhonda
    Crasta, Nicholas
    Brown, Lori
    Li, Xiaoxian
    Badve, Sunil
    Dhodapkar, Madhav
    Kalinsky, Kevin
    CANCER RESEARCH, 2024, 84 (09)
  • [19] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer.
    Delea, T. E.
    Karnon, J.
    Sofrygin, O.
    Thomas, S. K.
    Barghout, V
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S116 - S117
  • [20] Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Shah, Payal D.
    Moynahan, Mary Ellen
    Modi, Shanu
    Caravella, Betty Ann
    Datko, Farrah M.
    Zamora, Stephen
    Comen, Elizabeth
    Gilewski, Theresa
    Sugarman, Steven M.
    D'Andrea, Gabriella
    Lake, Diana E.
    Goldfarb, Shari B.
    Patil, Sujata
    Covey, Anne
    Berger, Michael F.
    Lacouture, Mario E.
    Norton, Larry
    Hudis, Clifford A.
    Baselga, Jose
    Chandarlapaty, Sarat
    Dickler, Maura N.
    CANCER RESEARCH, 2015, 75
12345